This involves exploring their correlation with CSF and plasma NfL, plasma p-tau181, p-tau217, and GFAP levels, using ultrasensitive detection technologies, examining their relationship with volumetric analyses of substructures of other brain regions to evaluate atrophy as a marker of neurodegeneration, as well as investigating genetic variations that could influence TIMP-1 expression in AD. This evidence concerns the gene NEFL and Alzheimer disease.